Literature DB >> 28987662

Value of DCE-MRI for staging and response evaluation in rectal cancer: A systematic review.

Rebecca A P Dijkhoff1, Regina G H Beets-Tan2, Doenja M J Lambregts3, Geerard L Beets4, Monique Maas5.   

Abstract

PURPOSE: Aim was to perform a systematic review to evaluate the clinical value of dynamic contrast-enhanced (DCE) MRI in rectal cancer. METHODS AND MATERIALS: A systematic search was performed on Pubmed, Embase and the Cochrane library. Studies that evaluated DCE-MRI for tumour aggressiveness, primary staging and restaging after chemoradiation (CRT) were included. Information on population, DCE technique, DCE parameters and outcome (angiogenesis, staging and response) were extracted.
RESULTS: 19 studies were identified; 10 evaluated quantitative analyses, 6 semiquantitative analyses and 3 evaluated both. 8 studies evaluated correlation between DCE-parameters and angiogenesis or tumour aggressiveness, 11 studies evaluated response prediction pre- and post-CRT. Semiquantitative washin parameters showed a significantly positive correlation with angiogenesis, while for quantitative analyses conflicting results were found. Conflicting results were also reported for the correlation between DCE parameters and tumour aggressiveness: both higher and lower vascularity in more aggressive tumours are reported, while some studies report no correlation. Six studies showed a predictive value of Ktrans for response. A high Ktrans pre-CRT was significantly correlated with a complete/good response, but the reported pre-CRT Ktrans varied substantially (0.36-1.93). After CRT a reduction in Ktrans of 32%-36% was significantly associated with response. For semiquantitative analyses pre-CRT late slope was reported to be significantly lower in good responders, however only few studies exist on semiquantitative analyses of post-CRT DCE-MRI.
CONCLUSION: DCE-MRI in rectal cancer is promising mainly for prediction and assessment of response to CRT, where a high pre-CRT Ktrans and a decrease in Ktrans are significantly predictive for response.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Contrast media; Dynamic contrast-enhanced; Magnetic resonance imaging; Rectal neoplasms; Response assessment

Mesh:

Substances:

Year:  2017        PMID: 28987662     DOI: 10.1016/j.ejrad.2017.08.009

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  22 in total

1.  Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.

Authors:  Eric Sorenson; Fernando Lambreton; Jian Q Yu; Tianyu Li; Crystal S Denlinger; Joshua E Meyer; Elin R Sigurdson; Jeffrey M Farma
Journal:  J Surg Res       Date:  2019-06-21       Impact factor: 2.192

Review 2.  MRI of Rectal Cancer: Tumor Staging, Imaging Techniques, and Management.

Authors:  Natally Horvat; Camila Carlos Tavares Rocha; Brunna Clemente Oliveira; Iva Petkovska; Marc J Gollub
Journal:  Radiographics       Date:  2019-02-15       Impact factor: 5.333

3.  Dynamic contrast-enhanced MRI model selection for predicting tumor aggressiveness in papillary thyroid cancers.

Authors:  Ramesh Paudyal; Yonggang Lu; Vaios Hatzoglou; Andre Moreira; Hilda E Stambuk; Jung Hun Oh; Kristen M Cunanan; David Aramburu Nunez; Yousef Mazaheri; Mithat Gonen; Alan Ho; James A Fagin; Richard J Wong; Ashok Shaha; R Michael Tuttle; Amita Shukla-Dave
Journal:  NMR Biomed       Date:  2019-11-04       Impact factor: 4.044

Review 4.  Current controversy, confusion, and imprecision in the use and interpretation of rectal MRI.

Authors:  Marc J Gollub; Chandana Lall; Neeraj Lalwani; Michael H Rosenthal
Journal:  Abdom Radiol (NY)       Date:  2019-11

Review 5.  Nonoperative Management for Rectal Cancer.

Authors:  Felipe F Quezada-Diaz; J Joshua Smith
Journal:  Hematol Oncol Clin North Am       Date:  2022-05-11       Impact factor: 2.861

Review 6.  Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples.

Authors:  Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello
Journal:  Abdom Radiol (NY)       Date:  2020-10-28

7.  Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer.

Authors:  Marc J Gollub; Ivana Blazic; Seth Felder; Andrea Knezevic; Mithat Gonen; Julio Garcia-Aguilar; P Phillip Paty; J Joshua Smith
Journal:  Eur Radiol       Date:  2018-09-21       Impact factor: 5.315

Review 8.  The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Authors:  Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-30       Impact factor: 7.038

9.  Diagnostic Performance of Vascular Permeability and Texture Parameters for Evaluating the Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Wenbing Ji; Jian Wang; Rongzhen Zhou; Minke Wang; Weizhen Wang; Peipei Pang; Min Kong; Chao Zhou
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

10.  Predicting Treatment Response of Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Amide Proton Transfer MRI Combined With Diffusion-Weighted Imaging.

Authors:  Weicui Chen; Liting Mao; Ling Li; Qiurong Wei; Shaowei Hu; Yongsong Ye; Jieping Feng; Bo Liu; Xian Liu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.